There is a Decreased Risk of Hospitalization from Heart Failure in Type II Diabetics Initiated on a SGLT2 Inhibitor When Compared to a GLP-1 Receptor Agonist

Dr. Huang Clinical question: Determine the cardiovascular risk outcome in type II diabetic patients initiated on an sodium-glucose cotransporter-2 (SGLT2)  inhibitor versus a glucagon-like peptide-1 (GLP-1) receptor agonist. Background: Various studies have suggested that several SGLT2 inhibitors and GLP-1 receptor agonists may improve cardiac outcomes—myocardial infarction, stroke, hospitalization for heart failure, and cardiovascular death. Current guidelines recommend using either an SGLT2 inhibitor or GLP-1 receptor agonist for patients with type II diabetes and cardiovascular disease. However, there has been no study directly comparing SGLT2 inhibitors with GLP-1 receptor agonists in patients with type II diabetes. Study design: 1:1 propensity matched, population-based, cohort study Setting: The data was retrieved from two commercial U.S. health insurance data sets: #1 Optum’s deidentified Clinformatics Data Mart and IBM Market Scan Database; and #2 Medicare fee-for-service Parts A, B, and D from April 1, 2013, to December 31, 2017. Synopsis: 186,040 propensity score-matched patients were stratified by cardiovascular disease status and analyzed to assess differences in cardiovascular risk in patients initiated on either an SGLT-2 inhibitor or GLP-1 receptor agonist. The primary outcome was a composite cardiovascular endpoint of hospitalization for acute myocardial infarction (MI), stroke, or heart failure. The median follow-up was approximately seven months. The in...
Source: The Hospitalist - Category: Hospital Management Authors: Tags: Diabetes Heart Failure In the Literature Source Type: research